Skip to main content
SpringerLink
Log in

The value of antinuclear antibodies in primary biliary cirrhosis

  • Original
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

Objective

Although autoantibodies have been used for the diagnosis of primary biliary cirrhosis (PBC), their role has not been clarified. In this study, we try to explore the value of gp210 antibody and anti-centromere antibodies (ACA) in PBC.

Methods

Anti-gp210 and ACA were tested in 140 PBC patients by ELISA and indirect immunofluorescence respectively. Their association with clinical, pathological data and prognosis was analysed.

Results

30.5% of PBC patients had positive anti-gp210 antibody and 29.2% had ACA. The anti-gp210 antibody positive group had higher Mayo risk scores and lower serum albumin levels compared to the negative one. Patients with positive anti-gp210 antibody were more likely to develop hepatic failure (p < 0.05, OR = 9.8460, 95% CI: 1.067–90.901) than patients with negative anti-gp210 antibody. More patients with positive ACA developed portal hypertension than patients with negative ACA (p < 0.05, OR = 9.259; 95% CI: 1.027–88.410). Furthermore, concurrent Sjögren’s syndrome (SjS) and PBC was significantly more likely in the ACA positive group than in the negative ones (68.4% in ACA positive group, 20.7% in ACA negative group p < 0.001).

Conclusions

Both anti-gp210 antibody and ACA are related to severe disease course and poor prognosis. For PBC patients with positive ACA, further examinations should be made to detect underlying SjS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rubin E, Schaffner F, Popper H (1965) Primary biliary cirrhosis. Am J Pathol 46:387–407

    PubMed  CAS  Google Scholar 

  2. Prince M, Chetwynd A, Newman W et al (2002) Survival and symptoms progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up to 28 years. Gastroenterology 123:1044–1051

    Article  PubMed  Google Scholar 

  3. Gershwin ME, Mackay IR (1991) Primary biliary cirrhosis: paradigm or paradox for autoimmunity. Gastroenterology 100:822–833

    PubMed  CAS  Google Scholar 

  4. Sherlock S, Sheuer PJ (1973) The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med 289:8534

    Google Scholar 

  5. Schaffner F (1975) Primary biliary cirrhosis. Clin Gastroenterol 4:351–366

    PubMed  CAS  Google Scholar 

  6. Kaplan MM (1987) Primary biliary cirrhosis. N Engl J Med 316:512–518

    Google Scholar 

  7. James SP, Hoofnagle JH, Strober W, Jones EA (1993) NIH conference: primary biliary cirrhosis: a model autoimmune disease. Ann Intern Med 99:500–502

    Google Scholar 

  8. Christensen E, Crowe J, Doniach D et al (1980) Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology 78:236–246

    PubMed  CAS  Google Scholar 

  9. Walker JG, Doniach D, Roitt IM, Sherlock S (1965) Serological tests in diagnosis of primary biliary cirrhosis. Lancet 39:827–831

    Article  Google Scholar 

  10. Talwalkar JA, Lindor KD (2003) Primary biliary cirrhosis. Lancet 362:53–61

    Article  PubMed  CAS  Google Scholar 

  11. Worman HJ, Courvalinc JC (2003) Antinuclear antibodies specific for primary biliary cirrhosis. Autoimmun Rev 2:211–217

    Article  PubMed  Google Scholar 

  12. Itoh S, Ichida T, Yoshida T et al (1998) Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J Gastroenterol Hepatol 13:257–265

    PubMed  CAS  Google Scholar 

  13. Invernizzi P, Podda M, Battezzati PM et al (2001) Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 34:366–372

    Article  PubMed  CAS  Google Scholar 

  14. Muratori P, Muratori L, Ferrari R et al (2003) Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 98:431–437

    Article  PubMed  Google Scholar 

  15. Nakamura M, Kondo H, Mori T et al (2007) Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 45:118–127

    Article  PubMed  CAS  Google Scholar 

  16. Yang W-H, Yu JH, Nakajima A et al (2004) Do antinuclear antibody in primary biliary cirrhosis patients identify increased risk for liver failure. Clin Gastroenterol Hepatol 2:1116–1122

    Article  PubMed  Google Scholar 

  17. Heathcote EJ (2000) Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases Practice Guideline. Hepatology 31:1005–1013

    Article  PubMed  CAS  Google Scholar 

  18. Angulo P, Batts KP, Therneau TM et al (1999) Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 29:644–647

    Article  PubMed  CAS  Google Scholar 

  19. Degott C, Zafrani ES, Callard P et al (1999) Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 29:1007–1012

    Article  PubMed  CAS  Google Scholar 

  20. Scheuer PJ (1967) Primary biliary cirrhosis. Proc R Soc Med 60:1257–1260

    PubMed  CAS  Google Scholar 

  21. Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis 61:554–558

    Article  PubMed  CAS  Google Scholar 

  22. Invernizzi P, Selmi C, Ranftler C et al (2005) Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 25:298–310

    Article  PubMed  Google Scholar 

  23. Wesierska-Gadek J, Penner E, Battezzati PM et al (2006) Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 43:1135–1144

    Article  PubMed  CAS  Google Scholar 

  24. Nakamura M, Shimizu-Yoshida Y, Takii Y et al (2005) Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol 42:386–392

    Article  PubMed  CAS  Google Scholar 

  25. Itoh S, Ichida T, Yoshida T et al (1998) Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J Gastroenterol Hepatol 13:257–265

    PubMed  CAS  Google Scholar 

  26. Invernizzi P, Podda M, Battezzati PM et al (2001) Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 34:366–372

    Article  PubMed  CAS  Google Scholar 

  27. Muratori P, Muratori L, Ferrari R et al (2003) Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 98:431–437

    Article  PubMed  Google Scholar 

  28. Nakamura M, Takii Y, Ito M et al (2006) Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis. J Autoimmun 26:138–145

    Article  PubMed  CAS  Google Scholar 

  29. Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y (2005) Clinical and serological heterogeneity in patients with anti-centromere antibodies. J Rheumatol 32:1488–1494

    PubMed  Google Scholar 

  30. Lee SL, Tsay GJ, Tsai RT (1993) Subjects with no apparent connective tissue disease. Ann Rheum Dis 52:586–589

    PubMed  CAS  Google Scholar 

  31. Tan EM, Rodana GP, Garcia I et al (1980) Diversity of antinuclear antibodies in progressive systemic sclerosis: anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 23:612–614

    Article  Google Scholar 

  32. Parveen S, Morshed SA, Nishiok M (1995) High prevalence of antibodies to recombinant CENP-B in primary biliary cirrhosis: nuclear immunofluorescence patterns and ELISA reactivities. J Gastroenterol Hepatol 10:438–445

    Article  PubMed  CAS  Google Scholar 

  33. Bernstein RM, Callender ME, Neuberger JM et al (1982) Anti-centromere antibodies in primary biliary cirrhosis. Ann Rheum Dis 41:612–614

    PubMed  CAS  Google Scholar 

  34. Makinen D, Fritzler M, Davis P, Sherlock S (1983) Anti-centromere antibodies in primary biliary cirrhosis. Arthritis Rheum 26:914–917

    Article  PubMed  CAS  Google Scholar 

  35. Rigamonti C, Shand LM, Feudjo M et al (2006) Clinical features and prognosis of primary biliary cirrhosis associated with systems sclerosis. Gut 55:388–394

    Article  PubMed  CAS  Google Scholar 

  36. Hossny E, Abdul HH, Mabrouk R (2000) Anti-centromere antibodies as a marker of Raynaud’s phenomenon in pediatric rheumatologic diseases. Pediatric Allergy Immunol 11:250–255

    Article  CAS  Google Scholar 

  37. Tsianos EV, Hoofnagle JH, Fox PC et al (1990) Sjögren’s syndrome in patients with primary biliary cirrhosis. Hepatology 11:730–734

    Article  PubMed  CAS  Google Scholar 

  38. Uddenfeldt P, Danielsson A, Forssell A et al (1991) Features of Sjögren’s syndrome in patients with primary biliary cirrhosis. J Intern Med 230:443–448

    Article  PubMed  CAS  Google Scholar 

  39. Coll J, Rives A, Griñó MC et al (1987) Prevalence of Sjögren’s syndrome in autoimmune diseases. Ann Rheum Dis 46:286–289

    PubMed  CAS  Google Scholar 

  40. Hsu TC, Chang CH, Lin MC et al (2006) Anti-CENP-H antibodies in patients with Sjögren’s syndrome. Rheumatol Int 26:298–303

    Article  PubMed  CAS  Google Scholar 

  41. Hida A, Kawabe Y, Kawakami A et al (1999) HTLV-I associated Sjögren’s syndrome is aetiologically distinct from anti-centromere antibodies positive Sjögren’s syndrome. Ann Rheum Dis 58:320–322

    PubMed  CAS  Google Scholar 

  42. Katano K, Kawano M, Koni I et al (2001) Clinical and laboratory features of anti-centromere antibody positive primary Sjögren’s syndrome. J Rheumatol 28:2238–2244

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology and Immunology, Peking Union Medical College Hospital Chinese Academy of Medical Sciences, Beijing, 100730, China

    Lixia Gao, Xinping Tian, Bin Liu & Fengchun Zhang

Authors
  1. Lixia Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xinping Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bin Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fengchun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fengchun Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gao, L., Tian, X., Liu, B. et al. The value of antinuclear antibodies in primary biliary cirrhosis. Clin. Exper.Med. 8, 9–15 (2008). https://doi.org/10.1007/s10238-008-0150-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-008-0150-6

Keywords

Search

Navigation